[{"id":"506639ea-1f9f-4169-b1e7-f028c834b64f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04870944","created_at":"2021-05-04T12:53:25.071Z","updated_at":"2025-02-25T15:12:04.041Z","phase":"Phase 1/2","brief_title":"CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma","source_id_and_acronym":"NCT04870944","lead_sponsor":"Children's Oncology Group","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CBL0137"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 01/28/2022","start_date":" 01/28/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-13"},{"id":"e7e0f9e8-9fa6-4272-881b-3d9ac0112ada","acronym":"BMX-GyCa-001","url":"https://clinicaltrials.gov/study/NCT06620029","created_at":"2025-02-26T15:00:07.320Z","updated_at":"2025-02-26T15:00:07.320Z","phase":"Phase 1/2","brief_title":"BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer","source_id_and_acronym":"NCT06620029 - BMX-GyCa-001","lead_sponsor":"BioMimetix JV, LLC","biomarkers":" BCL2 • TNFA","pipe":"","alterations":" ","tags":["BCL2 • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • BMX-001"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2024-10-01"},{"id":"37e6eb89-6b57-42a6-a515-a983cfbeb28c","acronym":"MK-7110-002","url":"https://clinicaltrials.gov/study/NCT02663622","created_at":"2021-01-18T12:58:52.613Z","updated_at":"2024-07-02T16:35:22.556Z","phase":"Phase 2","brief_title":"Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)","source_id_and_acronym":"NCT02663622 - MK-7110-002","lead_sponsor":"Oncoimmune, Inc., a subsidiary of Merck \u0026 Co., Inc. (Rahway, New Jersey USA)","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • Saccovid (efprezimod alfa)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 09/19/2016","start_date":" 09/19/2016","primary_txt":" Primary completion: 06/08/2020","primary_completion_date":" 06/08/2020","study_txt":" Completion: 05/18/2021","study_completion_date":" 05/18/2021","last_update_posted":"2024-01-23"},{"id":"7b1f29d9-a661-4502-922c-7d02d9bee371","acronym":"CATHY","url":"https://clinicaltrials.gov/study/NCT04976699","created_at":"2021-07-26T17:53:24.725Z","updated_at":"2024-07-02T16:36:27.451Z","phase":"Phase 3","brief_title":"CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)","source_id_and_acronym":"NCT04976699 - CATHY","lead_sponsor":"Merck Sharp \u0026 Dohme Corp.","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • Saccovid (efprezimod alfa)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 01/05/2021","start_date":" 01/05/2021","primary_txt":" Primary completion: 11/02/2021","primary_completion_date":" 11/02/2021","study_txt":" Completion: 11/02/2021","study_completion_date":" 11/02/2021","last_update_posted":"2021-07-26"}]